Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
| Professional Services Industry | Industrials Sector | Prahlad R. Singh CEO | LSE Exchange | 714046109 CUSIP |
| US Country | 11,000 Employees | 23 Oct 2026 Last Dividend | 4 Jun 2001 Last Split | - IPO Date |
Revvity, Inc., previously known as PerkinElmer, Inc., marks a significant name in the health sciences industry, offering comprehensive solutions, technologies, and services across the globe, including the Americas, Europe, Asia, and other international territories. With its inception in 1937 and headquarters in Waltham, Massachusetts, Revvity has grown to serve an expansive range of clients, including pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. Operating through two main segments - Life Sciences and Diagnostics - Revvity, Inc. brings forward a suite of instruments, reagents, informatics, software, and much more, catering to a wide array of testing, screening, and research needs in the health sciences sector.
Revvity, Inc.'s product portfolio and services are vast, covering various needs within the life sciences and diagnostics fields. Here's an overview of their most notable offerings: